

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Proteomics International Laboratories Ltd</b>
<b>ABN</b>	<b>78 169 979 971</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Neville Gardiner
<b>Date of last notice</b>	16 November 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect.
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Fertilus Pty Ltd as trustee for The Gardiner Family Trust  Mr Gardiner is director and shareholder of the trustee and a beneficiary of the trust.
<b>Date of change</b>	24 November 2022
<b>No. of securities held prior to change</b>	<i>Direct</i> Nil.  <i>Indirect</i> Nil.
<b>Class</b>	(a) Fully paid ordinary shares ( <b>Shares</b> ). (b) Unquoted options exercisable at \$1.32 per option on or before 24 November 2025 ( <b>Director C Options</b> ). (c) Unquoted options exercisable at \$1.76 per option on or before 24 November 2026 ( <b>Director D Options</b> ).
<b>Number acquired</b>	(a) 117,647 Shares. (b) 250,000 Director C Options. (c) 250,000 Director D Options.

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number disposed</b>	Not applicable.
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	(a) \$100,000.  (b) and (c) Non-cash consideration. Issue of equity incentive comprising unquoted options, being a cash-free, effective and efficient method of supplementing non-executive director's fees and recognising Mr Gardiner's commitment following his appointment as Non-Executive Chairman of the Company.  Estimated value based on an independent valuation: <ul style="list-style-type: none"> <li>• \$101,375 for Director C Options</li> <li>• \$103,575 for Director D Options.</li> </ul>
<b>No. of securities held after change</b>	<i>Direct</i> Nil.  <i>Indirect</i> 117,647 Shares. 250,000 Director C Options. 250,000 Director D Options
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	(a) Participation in placement following receipt of shareholder approval at the annual general meeting held on 24 November 2022 ( <b>2022 AGM</b> ).  (b) and (c) Issue of options following receipt of shareholder approval at the 2022 AGM.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Letter of appointment as Non-Executive Chairman of the Company.
<b>Nature of interest</b>	Offer of equity incentive comprising unquoted options, being a cash-free, effective and efficient method of supplementing non-executive director's fees and recognising Mr Gardiner's commitment upon appointment as Non-Executive Chairman of the Company.
<b>Name of registered holder (if issued securities)</b>	Fertilus Pty Ltd as trustee for The Gardiner Family Trust
<b>Date of change</b>	24 November 2022

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	Not applicable
<b>Interest acquired</b>	Nil
<b>Interest disposed</b>	Shareholder approval received to issue Director C and Director D Options.
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	<p>Non-cash consideration. Issue of equity incentive comprising unquoted options, being a cash-free, effective and efficient method of supplementing non-executive director's fees and recognising Mr Gardiner's commitment following his appointment as Non-Executive Chairman of the Company.</p> <p>Estimated value based on an independent valuation:</p> <ul style="list-style-type: none"> <li>• \$101,375 for Director C Options</li> <li>• \$103,575 for Director D Options.</li> </ul>
<b>Interest after change</b>	<p><i>Direct</i> Nil.</p> <p><i>Indirect</i> 117,647 Shares. 250,000 Director C Options. 250,000 Director D Options</p>

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

+ See chapter 19 for defined terms.

For personal use only

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Proteomics International Laboratories Ltd</b>
<b>ABN</b>	<b>78 169 979 971</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Robyn Elliott
<b>Date of last notice</b>	16 November 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Not applicable
<b>Date of change</b>	24 November 2022
<b>No. of securities held prior to change</b>	<i>Direct</i> Nil.  <i>Indirect</i> Nil.
<b>Class</b>	(a) Unquoted options exercisable at \$1.32 per option on or before 24 November 2025 ( <b>Director C Options</b> ). (b) Unquoted options exercisable at \$1.76 per option on or before 24 November 2026 ( <b>Director D Options</b> ).
<b>Number acquired</b>	(a) 125,000 Director C Options. (b) 125,000 Director D Options.
<b>Number disposed</b>	Not applicable.

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>Value/Consideration</b>          Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>Non-cash consideration. Issue of equity incentive comprising unquoted options, being a cash-free, effective and efficient method of supplementing non-executive director's fees and recognising Dr Elliott's commitment following her appointment as a non-executive director of the Company.</p> <p>Estimated value based on an independent valuation:</p> <ul style="list-style-type: none"> <li>• \$50,688 for Director C Options</li> <li>• \$51,788 for Director D Options.</li> </ul>
<p><b>No. of securities held after change</b></p>	<p><i>Direct</i>          Nil.</p> <p><i>Indirect</i>          125,000 Director C Options.          125,000 Director D Options</p>
<p><b>Nature of change</b>          Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Issue of options following receipt of shareholder approval at the annual general meeting held on 24 November 2022.</p>

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<p><b>Detail of contract</b></p>	<p>Letter of appointment as a non-executive director.</p>
<p><b>Nature of interest</b></p>	<p>Offer of equity incentive comprising unquoted options, being a cash-free, effective and efficient method of supplementing non-executive director's fees and recognising Dr Elliott's commitment upon appointment as a non-executive director of the Company.</p>
<p><b>Name of registered holder (if issued securities)</b></p>	<p>Robyn Elliott</p>
<p><b>Date of change</b></p>	<p>24 November 2022</p>
<p><b>No. and class of securities to which interest related prior to change</b>          Note: Details are only required for a contract in relation to which the interest has changed</p>	<p>Not applicable</p>
<p><b>Interest acquired</b></p>	<p>Nil</p>
<p><b>Interest disposed</b></p>	<p>Shareholder approval received to issue Director C and Director D Options.</p>

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation</p>	<p>Non-cash consideration. Issue of equity incentive comprising unquoted options, being a cash-free, effective and efficient method of supplementing non-executive director's fees and recognising Dr Elliott's commitment following her appointment as a non-executive director of the Company.</p> <p>Estimated value based on an independent valuation:</p> <ul style="list-style-type: none"> <li>• \$50,688 for Director C Options</li> <li>• \$51,788 for Director D Options.</li> </ul>
<p><b>Interest after change</b></p>	<p><i>Direct</i> Nil.</p> <p><i>Indirect</i> 125,000 Director C Options. 125,000 Director D Options</p>

**Part 3 - +Closed period**

<p><b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b></p>	<p>No.</p>
<p><b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b></p>	
<p><b>If prior written clearance was provided, on what date was this provided?</b></p>	

---

+ See chapter 19 for defined terms.

For personal use only

Rule 3.19A.2

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Proteomics International Laboratories Ltd</b>
<b>ABN</b>	<b>78 169 979 971</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Paul Edward House
<b>Date of last notice</b>	24 October 2022

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Baljuna Capital Pty Ltd  Mr House is a shareholder and director of the entity.
<b>Date of change</b>	24 November 2022
<b>No. of securities held prior to change</b>	<i>Direct</i> 343,864 fully paid ordinary shares (Shares).  <i>Indirect</i> 575,000 Shares.
<b>Class</b>	Shares.
<b>Number acquired</b>	117,647 Shares.
<b>Number disposed</b>	Not applicable.
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$100,000
<b>No. of securities held after change</b>	<i>Direct</i> 343,864 Shares.  <i>Indirect</i> 692,647 Shares.

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>Nature of change</b>          Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Participation in placement following receipt of shareholder approval at the annual general meeting held on 24 November 2022.</p>
--	---

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Not applicable.
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<p><b>No. and class of securities to which interest related prior to change</b>          Note: Details are only required for a contract in relation to which the interest has changed</p>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<p><b>Value/Consideration</b>          Note: If consideration is non-cash, provide details and an estimated valuation</p>	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<p><b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b></p>	No.
<p><b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b></p>	Not applicable
<p><b>If prior written clearance was provided, on what date was this provided?</b></p>	Not applicable

+ See chapter 19 for defined terms.

For personal use only



# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Proteomics International Laboratories Ltd</b>
<b>ABN</b>	<b>78 169 979 971</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Ian Roger Moore
<b>Date of last notice</b>	24 October 2022

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect.
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Moore and Sotomi Investments Pty Ltd as trustee for the Roger Moore Family A/C  Mr Moore is a director and shareholder of the trustee and a beneficiary of the trust.
<b>Date of change</b>	24 November 2022
<b>No. of securities held prior to change</b>	<i>Direct</i> Nil.  <i>Indirect</i> 917,000 fully paid ordinary shares ( <b>Shares</b> ).
<b>Class</b>	Shares.
<b>Number acquired</b>	58,824 Shares.
<b>Number disposed</b>	Not applicable.
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$50,000

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	<i>Direct</i> Nil.  <i>Indirect</i> 975,824 Shares.
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in placement following receipt of shareholder approval at the annual general meeting held on 24 November 2022.

**Part 2 - Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Not applicable.
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

**Part 3 - +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

+ See chapter 19 for defined terms.

For personal use only